Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05848219 · ClinicalTrials.gov registry record
Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- 543
- Enrollment target
NCT05848219 is a clinical trial that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 543 participants.
The verdict
NCT05848219 was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- 543 participants
- Enrollment target
Study Summary
This was a retrospective cohort study using the MarketScan health care administrative claim databases: Truven Health Analytics' MarketScan Commercial Claims and Encounters; MarketScan Medicare Supplement and Coordination of Benefit. We conducted this analysis using the most recent available data from the MarketScan database at the time of analysis, which was 01 June 2018 to 31 December 2020. We initiated this analysis from 01 June 2018 as encorafenib + binimetinib (enco/bini) was approved for patients with unresectable or metastatic melanoma with BRAF mutation at this time.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 543 participants |
| Start Date | 2021-10-16 |
| Est. Completion | 2022-04-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05848219
The ClinicalTrials.gov registry entry for NCT05848219 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 543 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05848219 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05848219 about?
NCT05848219 is a clinical study titled "Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib". This was a retrospective cohort study using the MarketScan health care administrative claim databases: Truven Health Analytics' MarketScan Commercial Claims and Encounters; MarketScan Medicare Supplement and Coordination of Benefit. We conducted this analysis using the most recent available data fro...
What is the current status of trial NCT05848219?
This trial is currently terminated. The enrollment target is 543 participants. The study started on 2021-10-16. Estimated completion is 2022-04-27.
Who is sponsoring clinical trial NCT05848219?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.